Exchange: NASDAQ·Updated 07:30 PM EST

MMSI News

News
all
press releases
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.
Zacks
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.
Zacks
More News
Merit Acquires Solo Pace For $45 Mln; Shares Down
(RTTNews) - Merit Medical Systems (MMSI) acquired Solo Pace, Inc., a Minneapolis-based manufacturer of temporary pacing technology used to treat patients with aortic stenosis. Merit, which had previously invested in Solo Pace, purchased the remaining shares on October 13, 2026, f...
Nasdaq News: Markets
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Zacks
These Analysts Boost Their Forecasts On Merit Medical Systems After Strong Q3 Results
Merit Medical beat Q3 estimates, raised FY2026 EPS guidance, narrowed sales outlook; analysts lifted price targets to $110 and $106.read more...
Benzinga
Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates
Merit Medical (MMSI) delivered earnings and revenue surprises of +7.69% and +1.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Merit Medical Systems Q3 2026 Earnings Call Transcript
Merit Medical Systems (NASDAQ:MMSI) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
Merit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
Zacks
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y
ECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital sales.
Zacks
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
Zacks

Advertisement|Remove ads.